MONTE ROSA THERAPEUTICS INC's ticker is GLUE and the CUSIP is 61225M102. A total of 70 filers reported holding MONTE ROSA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,506,518 | -47.0% | 1,472,331 | 0.0% | 2.38% | -32.2% |
| Q1 2024 | $10,379,934 | +24.8% | 1,472,331 | 0.0% | 3.51% | +41.6% |
| Q4 2023 | $8,318,670 | +18.0% | 1,472,331 | 0.0% | 2.48% | -14.6% |
| Q3 2023 | $7,052,465 | -30.1% | 1,472,331 | 0.0% | 2.91% | -41.2% |
| Q2 2023 | $10,085,467 | -12.1% | 1,472,331 | 0.0% | 4.94% | -10.5% |
| Q1 2023 | $11,469,458 | +2.4% | 1,472,331 | 0.0% | 5.52% | -25.4% |
| Q4 2022 | $11,204,439 | -6.9% | 1,472,331 | 0.0% | 7.40% | -7.4% |
| Q3 2022 | $12,029,000 | -15.5% | 1,472,331 | 0.0% | 7.99% | -21.4% |
| Q2 2022 | $14,237,000 | -31.0% | 1,472,331 | 0.0% | 10.16% | -8.8% |
| Q1 2022 | $20,642,000 | -31.3% | 1,472,331 | 0.0% | 11.14% | +5.0% |
| Q4 2021 | $30,065,000 | -8.3% | 1,472,331 | 0.0% | 10.61% | +62.2% |
| Q3 2021 | $32,804,000 | -1.8% | 1,472,331 | 0.0% | 6.54% | +22.2% |
| Q2 2021 | $33,422,000 | – | 1,472,331 | – | 5.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,472,331 | $32,804,000 | 6.54% |
| Cormorant Asset Management, LP | 3,102,199 | $67,957,000 | 2.76% |
| NEA Management Company, LLC | 7,703,205 | $171,627,000 | 2.04% |
| Avoro Capital Advisors LLC | 3,311,434 | $61,003,000 | 0.96% |
| Octagon Capital Advisors LP | 150,000 | $3,342,000 | 0.82% |
| Alphabet Inc. | 1,464,015 | $32,618,000 | 0.77% |
| Casdin Capital, LLC | 960,883 | $21,408,000 | 0.53% |
| RTW INVESTMENTS, LP | 1,214,572 | $26,005,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 119,647 | $2,666,000 | 0.22% |
| Avidity Partners Management LP | 300,000 | $6,684,000 | 0.15% |